Skip to main content

Table 3 Protein expression and genetic mutation by intrinsic subtypes

From: The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients

 

All cases

ER/PR + HER2-

ER/PR + HER2+

HER2 type

Basal-like

Unclassified

P

Cases (%)

471 (100)

306 (65.0)

41 (8.7)

59 (12.5)

37 (7.9)

28 (5.9)

 

EGFR

 

<0.01

Positive

74 (16.0)

16 (5.4)

5 (12.5)

19 (32.8)

34 (91.9)

0 (0)

Negative

388 (84.0)

283 (94.6)

35 (87.5)

39 (67.2)

3 (8.1)

28(100)

Missing

9

7

1

1

  

PTEN

 

<0.01

Reduced

234 (50.9)

156 (52.7)

18 (43.9)

16 (27.6)

28 (75.7)

16 (57.1)

Normal

226 (49.1)

140 (47.3)

23 (56.1)

42 (72.4)

9 (24.3)

12 (42.9)

Missing

11

10

 

1

  

IGF- 1R

0.77

Positive

397 (85.9)

255 (85.6)

36 (87.8)

50 (86.2)

30 (81.1)

26 (92.9)

Negative

65 (14.1)

43 (14.4)

5 (12.2)

8 (13.8)

7 (18.9)

2 (7.1)

Missing

9

8

 

1

  

Bcl- 2

<0.01

Positive

303 (65.0)

249 (83.0)

27 (67.5)

7 (12.1)

6 (16.2)

14 (50.0)

Negative

160 (35.0)

51 (17.0)

13 (32.5)

51 (87.9)

31 (83.8)

14 (50.0)

Missing

8

6

1

1

  

c- Kit

<0.01

Positive

33 (7.1)

15 (5.0)

0 (0)

7 (12.1)

10 (27.0)

1 (3.6)

Negative

433 (92.9)

287 (95.0)

41 (100)

51 (87.9)

27 (73.0)

27 (96.4)

Missing

5

4

 

1

  

c- Met

0.03

Positive

328 (72.6)

203 (69.5)

34 (82.9)

47 (85.5)

28 (75.7)

16 (59.3)

Negative

124 (27.4)

89 (30.5)

7 (17.1)

8 (14.5)

9 (24.3)

11 (40.7)

Missing

19

15

 

4

 

1

HIF- 1α

0.76

Positive

159 (34.1)

110 (36.4)

12 (29.3)

18 (31.0)

11 (29.7)

8 (28.6)

Negative

307 (65.9)

192 (63.6)

29 (70.7)

40 (69.0)

26 (70.2)

20 (71.4)

Missing

5

4

    

PDGFRA

0.49

Positive

393 (86.9)

255 (87.6)

34 (85.0)

52 (91.2)

30 (81.1)

22 (81.5)

Negative

59 (13.1)

36 (12.4)

6 (15.0)

5 (8.8)

7 (18.9)

5 (18.5)

Missing

19

15

1

2

 

1

Survivin

0.02

Positive

383 (82.4)

240 (79.5)

34 (85.0)

56 (96.6)

30 (81.1)

23 (82.1)

Negative

82 (17.6)

62 (20.5)

6 (15.0)

2 (3.4)

7 (18.9)

5 (18.9)

Missing

6

4

1

1

  

VEGFR2

0.59

Positive

318 (68.1)

206 (68.0)

25 (61.0)

44 (75.9)

25 (67.6)

18 (64.3)

Negative

149 (31.9)

97 (32.0)

16 (39.0)

14 (24.1)

12 (32.4)

10 (35.7)

Missing

4

3

 

1

  

VEGF- A

0.14

Positive

279 (60.4)

180 (60.0)

25 (61.0)

42 (72.4)

18 (48.6)

14 (50.0)

Negative

183 (39.6)

118 (40.0)

16 (39.0)

16 (27.6)

19 (51.4)

14 (50.0)

Missing

9

8

 

1

  

PIK3CA exon 9

0.94

Mutated

8 (8.8)

6 (9.7)

0 (0)

1 (10.0)

0 (0)

1 (14.3)

Wild type

83 (91.2)

56 (90.3)

6 (100)

9 (90.0)

6 (100)

6 (85.7)

Missing

380

45

35

49

31

22

PIK3CA exon 20

0.17

Mutated

28 (7.8)

20 (8.7)

4 (14.3)

1 (2.2)

3 (10.3)

0 (0)

Wild type

329 (92.2)

211 (91.3)

24 (85.7)

44 (97.8)

26 (89.7)

24 (100)

Missing

114

75

13

14

8

4

  1. EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, IGF-1R: insulin-like growth factor-1 receptor, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor, HIF-1α: hypoxia-inducible factor 1-alpha, PDGFRA: alpha-type platelet-derived growth factor receptor, VEGFR2: vascular endothelial growth factor receptor 2, VEGF-A: vascular endothelial growth factor A.
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us